Tumor necrosis factor-α, biologic agents and cardiovascular risk

Lupus

Volumn 14, Issue 9, 2005, Pages 780-784

  Sarzi Puttini, Piercarlo ^a   Atzeni, F ^a   Doria, A ^b   Iaccarino, L ^b   Turiel, M ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Biologic agents; Cardiovascular disease; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INDICATION; DRUG USE; DYSLIPIDEMIA; HEART MUSCLE CELL; HEART STRESS; HUMAN; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26244456758     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2220oa     Document Type: Review

References (33)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 223: 236-241.
2. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004; 99: 18-28.
3. von Haehling S, Anker SD. Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 2005; 14: 163-176.
4. Skapenko A, Kalden JR, Schulze-Koops H. Treatment of rheumatoid arthritis in the third millennium. Scand J Rheumatol 2001; 30: 249-254.
5. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140.
6. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602.
7. Haddy N, Sass C, Droesch S et al. IL-6, TNF-α and atherosclerosis risk indicators in healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-283.
8. Bazzoni F, Beutler B. The tumour necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-1725.
9. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of rumour necrosis factor α and the failing human heart. Curr Opin Cardiol 1999; 14: 206-210.
10. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-α in vitro. Am J Physiol 1995; 37: H517-H525.
11. Li YY, Feng YQ, Kadokami T et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci USA 2000; 97: 12746-12751.
12. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637-1652.
13. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumour necrosis factor-α in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
14. Panas D, Khadour FH, Szabo C, Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol 1998; 275: H1016-H1023.
15. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-389.
16. Agnoletti L, Curello S, Bachetti T et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-α. Circulation 1999; 100: 1983-1991.
17. Anker SD, Volterrnani M, Egerer KR et al. TNF-α as predictor of peak leg blood flow in chronic heart failure. Q J Med 1998; 91: 199-203.
18. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003; 177: 351-355.
19. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-248.
20. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin N Am 2004; 30: 349-364.
21. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-a rheumatoid arthritis and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4: 153-161.
22. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004; 50: 1040-1050.
23. α and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-518.
24. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994; 34: 17-40.
25. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155: 5038-5045.
26. Kadokami T, McTiernan CF, Frye CS et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000; 106: 589-597.
27. Kubota T, McNamara DM, Wang JJ et al. Effects of tumour necrosis factor gene polymorphisms on patients with congestive heart failure. VEST investigators for TNF-genotype-analysis. Vesnarinone Survival Trial. Circulation 1998; 97: 2499-2501.
28. Feldman AM, McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 2004; 4: 11-19.
29. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187.
30. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 1004-1007.
31. Popa C, Netea MG, Radstake T et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305.
32. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
33. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-311.